- Home
- ASH vs CPRX Comparison
ASH vs CPRX Comparison
Compare ASH & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASH
- CPRX
- Stock Information
- Founded
- ASH 1924
- CPRX 2002
- Country
- ASH United States
- CPRX United States
- Employees
- ASH N/A
- CPRX N/A
- Industry
- ASH Specialty Chemicals
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ASH Consumer Discretionary
- CPRX Health Care
- Exchange
- ASH Nasdaq
- CPRX Nasdaq
- Market Cap
- ASH 3.4B
- CPRX 2.8B
- IPO Year
- ASH N/A
- CPRX 2006
- Fundamental
- Price
- ASH $64.98
- CPRX $21.62
- Analyst Decision
- ASH Buy
- CPRX Strong Buy
- Analyst Count
- ASH 7
- CPRX 8
- Target Price
- ASH $93.50
- CPRX $32.25
- AVG Volume (30 Days)
- ASH 820.2K
- CPRX 902.0K
- Earning Date
- ASH 01-28-2025
- CPRX 02-26-2025
- Dividend Yield
- ASH 2.49%
- CPRX N/A
- EPS Growth
- ASH N/A
- CPRX 114.68
- EPS
- ASH N/A
- CPRX 1.18
- Revenue
- ASH $2,045,000,000.00
- CPRX $460,482,000.00
- Revenue This Year
- ASH N/A
- CPRX $24.00
- Revenue Next Year
- ASH $3.01
- CPRX $15.13
- P/E Ratio
- ASH N/A
- CPRX $18.34
- Revenue Growth
- ASH N/A
- CPRX 32.17
- 52 Week Low
- ASH $60.60
- CPRX $13.70
- 52 Week High
- ASH $102.50
- CPRX $24.64
- Technical
- Relative Strength Index (RSI)
- ASH 43.41
- CPRX 40.14
- Support Level
- ASH $63.44
- CPRX $22.18
- Resistance Level
- ASH $67.39
- CPRX $23.59
- Average True Range (ATR)
- ASH 1.67
- CPRX 0.70
- MACD
- ASH 0.40
- CPRX -0.17
- Stochastic Oscillator
- ASH 64.43
- CPRX 11.30
About ASH Ashland Inc.
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.